Novo Nordisk's Weight Loss Drug Ozempic Associated With Reduced Opioid, Alcohol Use Disorder Incidences, Study Shows
A study found that prescriptions for GIP/GLP-1 RA drugs may reduce opioid overdose and alcohol intoxication rates in patients with OUD and AUD, offering potential new treatments for addiction.
Judge Karen Marston held that, despite plaintiffs' arguments to the contrary, marketing discovery is not relevant to the ...
Wylie said: "Ozempic (semaglutide) is a medication licensed for the management of type 2 diabetes. While it has shown ...
Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...
The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of notable wins have me thinking this lead will widen. Earli ...
A coalition of unions, consumer groups, and public interest organizations has written to Lina Khan, Chair of the Federal ...
Novo Nordisk says Massachusetts plays a key role in its bid to expand beyond its historic focus as a diabetes and obesity ...
Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant ...
Danish drugmaker Novo Nordisk has made billions of dollars from its GLP-1s, including pills and injectable drugs like Ozempic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback